CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-12 | HIGH SUSANNA GATTI Chief Operating Officer | Option exercise 10b5-1 | +40,000 | $5.54 | $222K | 188,792 |
| 2024-06-12 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −26,036 | $33.17 | $864K | 162,756 |
| 2024-06-12 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −13,964 | $33.70 | $471K | 148,792 |
| 2024-06-12 | HIGH SUSANNA GATTI Chief Operating Officer | Option exercise · Stock option (right to buy) 10b5-1 | −40,000 | 100,486 | ||
| 2024-06-11 | Beskrovnaya Oxana Chief Scientific Officer | Sale | −2,136 | $31.34 | $67K | 147,511 |
| 2024-06-11 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,628 | $31.27 | $51K | 146,551 |
| 2024-06-11 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,008 | $31.27 | $32K | 145,543 |
| 2024-06-11 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −2,357 | $31.23 | $74K | 151,705 |
| 2024-06-11 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −2,913 | $31.23 | $91K | 148,792 |
| 2024-06-11 | McNeill Jonathan Chief Business Officer | Sale | −1,823 | $31.34 | $57K | 134,811 |
| 2024-06-11 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −1,331 | $31.34 | $42K | 113,774 |
| 2024-06-10 | HIGH SUSANNA GATTI Chief Operating Officer | Option exercise 10b5-1 | +80,000 | $5.54 | $443K | 234,062 |
| 2024-06-10 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −80,000 | $30.24 | $2.4M | 154,062 |
| 2024-06-10 | HIGH SUSANNA GATTI Chief Operating Officer | Option exercise · Stock option (right to buy) 10b5-1 | −80,000 | 140,486 | ||
| 2024-06-10 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −1,590 | $30.23 | $48K | 115,105 |
| 2024-05-22 | Stehman-Breen Catherine Director | Grant or award · Stock option (right to buy) | +25,133 | 25,133 | ||
| 2024-05-22 | Kersten Dirk Director | Grant or award · Stock option (right to buy) | +25,133 | 25,133 | ||
| 2024-05-22 | Incerti Carlo Director | Grant or award · Stock option (right to buy) | +25,133 | 25,133 | ||
| 2024-05-22 | HURWITZ EDWARD Director | Grant or award · Stock option (right to buy) | +25,133 | 25,133 | ||
| 2024-05-22 | Rhodes Jason P Director | Grant or award · Stock option (right to buy) | +25,133 | 25,133 |
Page 18 of 29 · 561 trades